A Phase II Study of CCI-779 [temsirolimus] in B-Cell Lymphoma and Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Phase II Study of CCI-779 [temsirolimus] in B-Cell Lymphoma and Chronic Lymphocytic Leukemia (CLL).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Temsirolimus (Primary)
  • Indications B cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse lymphoma; Follicular lymphoma; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Apr 2012 Actual patient number is 39 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual patient number is 39 as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Actual end date (1 Nov 2010) added as reported by ClinicalTrials.gov. (NCT00290472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top